Limited Submission Funding Opportunities – updated 9/17/21

Please be aware that any grant that brings in less than 15% in indirect costs (IDC) will need to be supplemented up to the 15% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submitting a proposal. Training fellowships from foundations, public charity, and non-profit organizations are excluded from this minimum IDC requirement.

For MGH investigators selected through a competitive process as the institutional nominee for any limited submission funding opportunities, in situations in which the grant will bring in less than 15% indirect cost (IDC), ECOR will cover the IDC gap up to a maximum of \$50,000 per year. In order to optimize the distribution of limited ECOR funds across the MGH research community, it is expected that PIs and departments will work together to cover the remaining IDC shortfall.

This policy is <u>only effective</u> for those limited submission opportunities in which MGH is invited to submit its own nominee(s). This policy does not apply for those limited submission opportunities in which the MGH investigator must apply through HMS.

For further questions, please contact ECOR at ecor@mgh.harvard.edu

We ask that all MGH Investigators interested in applying for any limited submission award submit a Letter of Intent (see detailed instructions below) to the MGH Executive Committee on Research (ECOR) by the deadline indicated for each award to be considered to receive an institutional nomination.

Process

Submit a one- to two-page Letter of Intent (LOI) to the MGH Executive Committee on Research (ECOR) via email to ecor@mgh.harvard.edu. In addition to your LOI, please include an NIH Biosketch.

The letter of intent should include:

- 1. Name of the Principal Investigator with appropriate contact information
- 2. A descriptive title of the potential application
- 3. Brief description of the project
- 4. Brief description of why you specifically should be selected to receive institutional nomination for this award

In the event that there is more than one MGH investigator interested in applying for a limited submission award, the LOIs will be used to assess candidates and a review and selection process will take place.

If there is a limited submission funding opportunity you do not see listed below or you have any additional questions, please let us know at ecor@mgh.harvard.edu.

CURRENT OPPORTUNITIES

1. Pediatric Centers of Excellence in Nephrology (P50 Clinical Trial Optional) https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-21-024.html

MGH LOI Deadline: 9/22/21 NIH LOI Deadline: 10/18/21

NIH Application Deadline: 11/18/21

This Funding Opportunity Announcement (FOA) invites applications for the Pediatric Centers of Excellence in Nephrology (PCEN) to support basic, translational and clinical research in pediatric kidney disease. The goals of this program are: 1. to attract new scientific expertise to the study of human pediatric renal physiology, kidney development, and pediatric kidney disorders; 2. to encourage multidisciplinary research in these areas; and 3. to develop the pediatric nephrology research

Limited Submission Funding Opportunities – updated 9/17/21

community through a national research symposium, broad sharing of research resources, and a national Pilot and Feasibility grant program. These efforts are expected to lead to innovative approaches to study kidney disease in children and the eventual submission of substantial, competitive, investigator—initiated research applications. The PCEN will complement the O'Brien Kidney and Urological Research Centers and are expected to leverage existing institutional resources which may include Clinical Translational Science Awards, Institutional Network Awards for Promoting Kidney, Urologic, and Hematologic Research Training (U2C/TL1), and other NIDDK-Division of Kidney, Urologic and Hematologic Diseases (KUH)-funded consortia.

 National Program for the Career Development of Physician Scientists in Diabetes Research (Diabetes – Docs) (K12 Clinical Trial Optional)

https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-21-019.html

MGH LOI Deadline: 9/28/21

NIH Application Deadline: 11/18/21

The purpose of the Diabetes-Docs Program is to support the career development of physicians committed to a career in diabetes research. The program is intended to remedy the dearth of pediatric endocrinologists and physicians from other specialties conducting innovative research into the causes and consequences of diabetes. Diabetes-Docs will be a single national program, implemented by one or more PD/PIs, together with an advisory committee composed of basic and clinical investigators who have a strong record of funded research and successful training of physician-scientists. Although there will be one national administrative center awardee, scholars are expected to be appointed and supported at their home institutions around the country. The program will have a focus on Type 1 Diabetes (T1D) research, with the major funding from the Statutory Special Diabetes

Program https://www.niddk.nih.gov/about-niddk/research-areas/diabetes/type-1-diabetes-special-statutory-funding-program/about-special-diabetes-program. Starting in the second year, the program will expand to support the career development of physicians whose research focuses on innovative projects in type 2 diabetes. The program is expected to deliver on goals to increase the diversity of physician

 ${\bf NIDDK}\ \underline{https://www.niddk.nih.gov/research-funding/research-programs\#diabetes.}$

scientists with independent research careers in the mission of

This Funding Opportunity Announcement (FOA) allows appointment of Scholars (K12) proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary clinical trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development.

3. Genome Research Experiences to Attract Talented Undergraduates into the Genomics Field to Enhance Diversity (R25 Clinical Trial Not Allowed)

https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-21-033.html

MGH LOI Deadline: 10/01/21 NIH LOI Deadline: 11/01/21

NIH Application Deadline: 12/01/21

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NHGRI R25 program is to support educational activities that encourage undergraduates from diverse backgrounds, including those from groups underrepresented in the biomedical workforce, to pursue further training and careers in the scientific, medical, ethical, social and/or legal areas of genomics research.

Limited Submission Funding Opportunities – updated 9/17/21

To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on:

- Research Experiences
- Courses for Skills Development

This Genome Research Experiences to Attract Talented Undergraduates into the Genomic Field to Promote Diversity (GREAT) Program will support collaborative institutional partnerships that provide research education programs for undergraduates enrolled at minority-serving institutions (MSIs) or Institutional Development Award (IDeA)-eligible institutions. A partnership will include a MSI or IDeA-eligible institution, and one or more research-intensive institutions or organizations with a suitable research base for graduate-level training in scientific areas of interest to NHGRI.

4. Responsive Grants, Retirement Research Foundation (RRF) - NEW! https://www.rrf.org/apply-for-a-grant/

MGH LOI Deadline: 11/01/21 Sponsor LOI Deadline: 11/15/21

Sponsor Application Deadline (Invited): 2/1/22

RRF Foundation for Aging focuses on improving the quality of life for older people. In an effort to strengthen the Foundation's impact, RRF has established Priority Areas. These Priority Areas are specific topics in aging that will be given higher priority within the Foundation's grantmaking program.

Types of Grants

- 1. Advocacy: Achieve enduring social change around issues that affect older Americans
- 2. **Direct Service:** Improve availability and quality of community-based services and supports in seven states
- 3. Research: Seek causes and solutions to significant problems for older persons
- 4. **Professional Education & Training:** Increase the competency of professionals and paraprofessionals who serve older people
- 5. **Organizational Capacity Building:** Improve management and governance of non-profit organizations
- 5. NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) Genetic Research Centers (GRCs) (U01 Clinical Trial Optional)

https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-21-022.html

MGH LOI Deadline: 11/02/21 NIH LOI Deadline: 11/21/21

NIH Application Deadline: 12/21/21

The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) was established in July 2002 for the purpose of identifying genetic variation predisposing to Inflammatory Bowel Disease (IBD). Since its establishment and in collaboration with the International IBD Genetics Consortium, the NIDDK IBDGC has identified over 250 IBD susceptibility loci. However, for the great majority of these loci, the specific causal variants and effector genes have not yet been identified, and the biological mechanisms through which these variants influence IBD pathophysiology remain to be elucidated. The purpose of this Funding Opportunity Announcement (FOA) is to renew the IBDGC with a continued mission to characterize the genetic architecture of IBD phenotypes, particularly in populations currently underrepresented in IBD genomic studies, and to elucidate the biological mechanisms by which genetic variants influence IBD pathophysiology, phenotypes and clinical course. The Genetic Research Centers (GRCs) of the IBDGC will serve as sites for enrollment of IBD patients, relatives and healthy controls, for laboratory-based studies on biological samples obtained from these subjects, and for mechanistic studies of the risk variants identified, and of the genes, proteins and pathways they impact.